<DOC>
	<DOCNO>NCT01947140</DOCNO>
	<brief_summary>This study test safe combination drug Romidepsin Pralatrexate patient lymphoid malignancy determine dose combination drug safest . If combination determine safe , study continue accrual patient peripheral T-Cell lymphoma ( PTCL ) .</brief_summary>
	<brief_title>Pralatrexate + Romidepsin Relapsed/Refractory Lymphoid Malignancies</brief_title>
	<detailed_description>The non- Hodgkin lymphoma ( NHL ) represent heterogeneous group malignancy . Under rubric lymphoma exist fast grow cancer know science , ( Burkett 's lymphoma , lymphoblastic lymphoma/leukemia ) , well indolent ( small lymphocytic lymphoma , follicular lymphoma , marginal zone lymphoma ) . This remarkable diversity biology impose significant challenge . Researchers seek understand cell origin differentiate sometimes subtle difference relate sub-types disease ; identify best treatment subtypes , ever-increasing likelihood new understand molecular pathogenesis disease result increase new drug specific target population .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Phase I : Patients must histologically confirm relapsed refractory NonHodgkin 's lymphoma , Hodgkin 's Disease multiple myeloma ( defined World Health Organization ( WHO ) criterion ) . Phase II : Patients must histologically confirm relapsed refractory TCell Lymphoma ( define WHO criterion ) . Must receive first line chemotherapy . No upper limit number prior therapy Evaluable Disease Age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Patients must adequate organ marrow function define protocol Adequate Contraception Ability understand willingness sign write informed consent document Inclusion Criteria Multiple Myeloma patient specify protocol Prior Therapy Exposure chemotherapy radiotherapy within 2 week ( 6 week nitrosureas mitomycin C ) prior enter study recover adverse event due agent administer 2 week earlier Systemic steroid stabilize equivalent ≤10 mg/day prednisone prior start study drug No investigational agent allow Central nervous system metastasis , include lymphomatous meningitis History allergic reaction Pralatrexate Romidepsin Uncontrolled intercurrent illness Pregnant woman Nursing woman Current malignancy history prior malignancy , outline protocol Patient know Human Immunodeficiency Virus ( HIV ) positive Active Hepatitis A , Hepatitis B , Hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoid Malignancies</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Non-hodgkin Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Anaplastic Large Cell Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
	<keyword>Peripheral T-cell Lymphoma</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
</DOC>